Your browser is no longer supported. Please, upgrade your browser.
MNKD MannKind Corporation daily Stock Chart
MannKind Corporation
Index- P/E0.74 EPS (ttm)1.26 Insider Own0.10% Shs Outstand100.28M Perf Week-30.45%
Market Cap92.76M Forward P/E- EPS next Y-0.92 Insider Trans15.67% Shs Float73.40M Perf Month-54.21%
Income125.70M PEG0.03 EPS next Q-0.09 Inst Own19.50% Short Float26.55% Perf Quarter44.96%
Sales174.80M P/S0.53 EPS this Y130.10% Inst Trans-0.16% Short Ratio6.63 Perf Half Y97.19%
Book/sh-1.92 P/B- EPS next Y-5.70% ROA115.30% Target Price- Perf Year-41.46%
Cash/sh0.23 P/C4.05 EPS next 5Y26.80% ROE-43.20% 52W Range0.41 - 2.38 Perf YTD45.28%
Dividend- P/FCF- EPS past 5Y17.20% ROI-396.80% 52W High-61.68% Beta3.35
Dividend %- Quick Ratio0.80 Sales past 5Y411.30% Gross Margin84.30% 52W Low122.46% ATR0.15
Employees153 Current Ratio0.80 Sales Q/Q- Oper. Margin79.70% RSI (14)35.00 Volatility12.83% 10.61%
OptionableYes Debt/Eq- EPS Q/Q117.10% Profit Margin71.90% Rel Volume1.16 Prev Close0.93
ShortableNo LT Debt/Eq- EarningsMar 16 BMO Payout0.00% Avg Volume2.94M Price0.91
Recom4.00 SMA20-33.46% SMA50-30.46% SMA2006.15% Volume2,750,034 Change-1.39%
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-12-14Reiterated RBC Capital Mkts Outperform $16 → $13
Jul-01-14Downgrade MLV & Co Buy → Hold $11
Jun-30-14Reiterated Brinson Patrick Market Outperform $12 → $15
Jun-13-14Initiated RBC Capital Mkts Outperform $16
Apr-02-14Reiterated MLV & Co Buy $9 → $11
Jun-27-13Reiterated MLV & Co Buy $6 → $8
May-15-13Initiated MLV & Co Buy $6
Apr-13-12Initiated Cowen & Co Neutral
Feb-23-12Reiterated JMP Securities Mkt Outperform $7 → $5
Aug-12-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $7
Apr-20-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind Accesswire
Apr-10-17 04:22PM  Is MannKind Corporation Getting Ready to Sell? Motley Fool -5.26%
Apr-06-17 08:09AM  Sometimes Your Smartest Investing Move Is to Remain on the Sidelines Motley Fool
Apr-03-17 09:30AM  Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand Accesswire -6.76%
Mar-31-17 08:05AM  3 Companies That Might Not Live to See 2020 Motley Fool
Mar-27-17 10:30AM  Short Interest Pulls Back in Major Biotechs
Mar-23-17 01:04PM  MANNKIND CORP Financials
Mar-22-17 09:23AM  Billionaires' Worst Healthcare Stock Picks for 2017 (So Far) Motley Fool
Mar-21-17 04:23PM  Could MannKind Corporation's Marketing Blitz Pay Off? Motley Fool -5.91%
Mar-20-17 09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now 24/7 Wall St.
Mar-17-17 04:34PM  MANNKIND CORP Files SEC form 8-K, Other Events +7.25%
02:44PM  Edited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT Thomson Reuters StreetEvents
Mar-16-17 04:38PM  MannKind posts 4Q profit Associated Press
04:17PM  MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results GlobeNewswire
09:30AM  When Profit Makers Can Be Active Profit Takers Accesswire
07:07AM  Q4 2016 MannKind Corp Earnings Release - Before Market Open
Mar-14-17 12:04PM  Top 10 Long/Short Estimize Signal Scores [Week 3/13]
Mar-13-17 12:12PM  3 Companies That Probably Won't Survive Till 2019 at Motley Fool
Mar-10-17 10:30AM  Major Biotechs See a Retreat in Short Interest
06:15AM  The 6 Most Shorted Nasdaq Stocks
Mar-09-17 10:06AM  Better Buy: MannKind Corp. vs. Dexcom at Motley Fool
Mar-08-17 09:00AM  MannKind Corporation and Charles Mattocks Announce REVERSED-Americas First Docu-Series Tackling Diabetes GlobeNewswire
Mar-07-17 12:27PM  Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February at Motley Fool
09:00AM  MannKind Corporation Announces Upcoming Events GlobeNewswire
Mar-06-17 09:54AM  Two Biotechs To Watch This Week: Novan Inc (NOVN) And MannKind Corporation (MNKD) at Insider Monkey -11.06%
Mar-03-17 11:39AM  Why MannKind Corporation Stock Is Sinking Today at Motley Fool +336.08%
Mar-02-17 08:02AM  MANNKIND CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matt -8.37%
Feb-28-17 11:03AM  3 Stocks to Avoid in Biotech at Motley Fool
10:15AM  Short Sellers Hike Their Bets in Major Biotechs
06:20AM  The 6 Most Shorted Nasdaq Stocks
Feb-27-17 01:58PM  Can MannKind Be Saved? at
Feb-23-17 04:55PM  MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Feb-21-17 09:00AM  MannKind Receives $16.7 Million From Sale of Valencia Property GlobeNewswire
Feb-10-17 09:55AM  Major Biotechs Scare Off Loads of Short Sellers
06:35AM  The 6 Most Shorted Nasdaq Stocks
Feb-07-17 10:16AM  Here's Why MannKind Corporation Rose 11.5% in January at Motley Fool -5.14%
Feb-03-17 08:46AM  Good News and Bad News for MannKind Corporation at Motley Fool
Feb-02-17 02:59PM  MannKind Looks to Boost Flagging Afrezza Sales at Investopedia -17.14%
01:08PM  Mannkind in Free Fall After Changes to Insulin Product, Sales Force
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
09:00AM  MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza® Growth GlobeNewswire
Jan-27-17 09:00AM  MannKind Corporation to Hold Investor Conference Call on February 1, 2017 GlobeNewswire
Jan-26-17 10:35AM  Short Sellers Back Off Major Biotechs
06:25AM  The 6 Most Shorted Nasdaq Stocks
Jan-23-17 09:01AM  Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open +8.13%
Jan-18-17 03:56PM  MannKind Has a New Plan, but Will It Work? at Motley Fool
Jan-12-17 04:00PM  Insulin Drug Offers Hope for MannKind
09:35AM  Biotech Short Sellers Run for Cover
08:02AM  MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
06:35AM  The 6 Most Shorted Nasdaq Stocks
Jan-10-17 04:50PM  MANNKIND CORP Files SEC form 8-K, Other Events
Jan-09-17 12:08PM  Is MannKind Corp. Ready to Rebound in 2017? at Motley Fool -5.57%
09:00AM  MannKind Receives $30.6 Million From Sanofi GlobeNewswire
Jan-05-17 10:27AM  CORRECTING AND REPLACING -- MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
09:00AM  MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
Jan-04-17 09:00AM  MannKind Announces Key Addition to Its Executive Management Ranks GlobeNewswire +7.41%
Jan-03-17 09:00AM  MannKind Receives $1 Million Milestone From RLS GlobeNewswire
Dec-29-16 10:08AM  Galena Biopharma Reveals Regulatory Pathway for GALE-401
09:30AM featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
04:44AM  MannKind (MNKD) Shares March Higher, Can It Continue?
Dec-28-16 10:10AM  Biotech Short Interest Sinks
06:25AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Dec-27-16 01:42PM  Nate Pile's Top Recommendations For 2017 at Forbes
Dec-22-16 02:54PM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point at TheStreet
08:03AM  Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
Dec-21-16 08:42AM  Celgene (CELG) Otezla Approved in Japan for Two Indications -9.37%
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 08:42AM  Why MannKind (MNKD) Might Be a Diamond in the Rough +27.66%
Dec-18-16 07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-15-16 10:06AM  Is MannKind Corporation (MNKD) a Good Stock to Buy? at Insider Monkey
06:27AM  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
Dec-14-16 09:17AM  Envision Healthcare Acquires Desert Mountain Consultants
07:39AM  Proteon Slips to 52-Week Low on Kidney Disease Study Data
Dec-13-16 01:11PM  ETFs with exposure to MannKind Corp. : December 13, 2016
09:30AM featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger
Dec-12-16 09:10AM  Biotech Short Interest Remains Mixed -5.26%
08:35AM  Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
06:35AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Dec-09-16 09:51AM  Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
Dec-07-16 08:55AM  Theravance Stock Up on Fast Track Status for Velusetrag
08:18AM  Better Buy: MannKind Corp. vs. Novo Nordisk at Motley Fool
08:01AM  MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Dec-06-16 10:07AM  Biotech's Dumbest CEO Moves in 2016 at Motley Fool +10.42%
Dec-01-16 11:24AM  MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions
Nov-28-16 09:47AM  3 Biotech Investing Tips That Could Earn You Thousands at Motley Fool
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
06:55AM  10 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Nov-20-16 07:26AM  Penny Stocks: 2 to Buy, 2 to Avoid at Motley Fool
Nov-14-16 08:35AM  A Trump Victory Sparks Stock Market Surge
08:05AM  MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Nov-11-16 01:26PM  These 5 Stocks Under $10 Could Make You a Lot of Money +6.45%
12:56PM  Sanofi Gets Hosed on MannKind Deal (SNY, MNKD) at Investopedia
11:32AM  Edited Transcript of MNKD earnings conference call or presentation 9-Nov-16 10:00pm GMT
Nov-10-16 03:32PM  Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi +33.16%
12:58PM  MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing
11:55AM  Why MannKind Corp. Stock Skyrocketed Today at Motley Fool
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFEFFER MATTHEW JCEO, CFO, DirectorJan 03Buy0.544,5402,452403,085Jan 04 01:21 PM
Alinaya Rosabel RealicaSVP, Prin Acctg OfficerJan 03Buy0.549,0434,883140,456Jan 04 01:20 PM
Castagna MichaelChief Commercial OfficerAug 26Buy0.7817,50013,650212,500Aug 29 08:53 AM
Castagna MichaelChief Commercial OfficerAug 24Buy0.8715,00013,050195,000Aug 24 06:43 PM
Castagna MichaelChief Commercial OfficerAug 23Buy0.9425,00023,468180,000Aug 24 08:41 AM
PFEFFER MATTHEW JCEO, CFO, DirectorAug 15Buy0.9925,00024,650397,996Aug 16 07:54 AM
Castagna MichaelChief Commercial OfficerAug 12Buy1.0025,00024,88875,000Aug 16 07:56 AM
Alinaya Rosabel RealicaSVP, Prin Acctg OfficerJul 06Sale1.066,2946,672131,413Jul 18 06:30 PM
Castagna MichaelChief Commercial OfficerMay 17Buy0.9350,00046,50050,000May 18 08:00 AM